Physician Video

Please see Important Safety Information and Full Prescribing Information

INDICATION

EUFLEXXA (1% sodium hyaluronate) is used to relieve knee pain due to osteoarthritis. It is used for patients who do not get enough relief from simple pain medications such as acetaminophen or from exercise and physical therapy.

EUFLEXXA is only for injection into the knee, performed by a doctor or other qualified healthcare professional.

IMPORTANT SAFETY INFORMATION

  • Do not take this product if you have had any previous allergic reaction to EUFLEXXA or hyaluronan products.
  • You should not have EUFLEXXA injected into the knee if you have a knee joint infection or skin diseases or infections around the injection site.
  • EUFLEXXA has not been tested in pregnant women, women who are nursing or in children less than 18 years of age. After you receive your EUFLEXXA injection you should avoid physical activities for 48 hours such as jogging, tennis, heavy lifting, or standing on your feet for a long time (more than one hour at a time).
  • The most common adverse events related to EUFLEXXA injections were joint pain, back pain, limb pain, muscle pain, and joint swelling.

You are encouraged to report negative side effects of prescription drugs to the FDA.

Visit www.FDA.gov/medwatch or call 1-800-FDA-1088.

You may also contact Ferring Pharmaceuticals Inc. at 1-888-FERRING.

Please see Important Safety Information and Full Prescribing Information

INDICATION

EUFLEXXA (1% sodium hyaluronate) is used to relieve knee pain due to osteoarthritis. It is used for patients who do not get enough relief from simple pain medications such as acetaminophen or from exercise and physical therapy.

EUFLEXXA is only for injection into the knee, performed by a doctor or other qualified healthcare professional.

IMPORTANT SAFETY INFORMATION

  • Do not take this product if you have had any previous allergic reaction to EUFLEXXA or hyaluronan products.
  • You should not have EUFLEXXA injected into the knee if you have a knee joint infection or skin diseases or infections around the injection site.
  • EUFLEXXA has not been tested in pregnant women, women who are nursing or in children less than 18 years of age. After you receive your EUFLEXXA injection you should avoid physical activities for 48 hours such as jogging, tennis, heavy lifting, or standing on your feet for a long time (more than one hour at a time).
  • The most common adverse events related to EUFLEXXA injections were joint pain, back pain, limb pain, muscle pain, and joint swelling.

You are encouraged to report negative side effects of prescription drugs to the FDA.

Visit www.FDA.gov/medwatch or call 1-800-FDA-1088.

You may also contact Ferring Pharmaceuticals Inc. at 1-888-FERRING.